Celler Therapeutics

Celler Therapeutics is a Malaysian biotechnology company specializing in regenerative medicine and advanced cell-based therapies. As a subsidiary of Ascendnex, the company focuses on the development and commercialization of human mesenchymal stem cell (MSC) products and CAR-T cell therapies. Their primary research and clinical efforts target chronic conditions such as Type 2 diabetes, myocardial infarction, and knee osteoarthritis. Celler Therapeutics operates within a synergistic ecosystem that includes manufacturing and clinical partnerships with leading academic institutions like Universiti Kebangsaan Malaysia (UKM) and Universiti Malaysia Sabah (UMS). The company aims to make precision-engineered regenerative treatments accessible across Southeast Asia and underserved global regions.